Posted by Michael Wonder on 17 Nov 2016
Centrexion Therapeutics announces fast track designation granted by FDA to CNTX-4975 for treatment of Morton’s neuroma
15 November 2016 - CNTX-4975 has potential to be the first non-surgical FDA-approved treatment for orphan disease, painful foot nerve disorder.
Centrexion Therapeutics, a company focused on advancing the treatment of chronic moderate to severe pain with one of the largest exclusively pain-focused pipelines of non-opioid therapies in active development, today announced that the U.S. FDA has granted Fast Track designation to CNTX-4975 for the treatment of Morton’s neuroma, a rare, painful nerve disorder in the foot.
CNTX-4975, Centrexion’s proprietary lead pipeline candidate, is a highly potent, ultrapure, synthetic form of capsaicin (originally derived from the chili plant), called trans-capsaicin, that is designed to be injected directly into the site of pain to provide rapid onset analgesia and a long duration of relief.
